1. Articles from Newswise

    newswise.com

  2. 1-24 of 72 1 2 3 »
    1. Researchers Identify Gene Variants Linked to a High-Risk Children's Cancer

      Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery, in the MMP20 gene, may assist doctors in better diagnosing subtypes of neuroblastoma.

      Read Full Article
      Mentions: Genetics
    2. Does Health Insurance Status Affect Childhood Cancer Survival?

      Does Health Insurance Status Affect Childhood Cancer Survival?

      Privately insured children and those with Medicaid at the time of a cancer diagnosis experience largely similar survival trends, with slight evidence for an increased risk of cancer death in children who were uninsured at diagnosis, finds a new study from the Brown School at Washington University in St. Louis.

      Read Full Article
    3. CHLA Researcher Awarded $1.9 Million by NIH to Study Novel Approach to Battling Neuroblastoma

      CHLA Researcher Awarded $1.9 Million by NIH to Study Novel Approach to Battling Neuroblastoma

      Muller Fabbri, MD, PhD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, has been awarded $1.9 million by the National Cancer Institute of the NIH to further his research on neuroblastoma.

      Read Full Article
    4. New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      The Treehouse Childhood Cancer Initiative researchers at UC Santa Cruz Genomics Institute and the St. Baldrick's Foundation are making a 11,000+ tumor database available for use by all researchers in the pediatric cancer community and beyond in our continued battle to take childhood back from cancer. The database contains RNA-Seq gene expression data, as well as age, disease, and sex.

      Read Full Article
      Mentions: Genetics
    5. Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

      Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

      After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent.

      Read Full Article
    6. Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.

      Read Full Article
    7. Dynamic Changes, Regulatory Rewiring Occur as T Cells Respond to Infection

      "Researchers from Children’s Hospital of Philadelphia (CHOP) and the University of Iowa used sophisticated sequencing and computational techniques to investigate the molecular mechanisms during each stage of the CD8+ T cells’ responses. By identifying novel biological pathways and publishing details of these interactions, the study team aims to help uncover useful targets in developing better vaccines and cancer treatments."

      Read Full Article
    8. University of Pennsylvania to Join First-of-Its-Kind Research Collaboration to Fight Cancer with New Immunotherapies

      University of Pennsylvania to Join First-of-Its-Kind Research Collaboration to Fight Cancer with New Immunotherapies

      “We are at an inflection point in cancer research and now is the time to maximize immunotherapy’s unique potential to transform all cancers into manageable diseases, saving millions of lives,” said Sean Parker, President of The Parker Foundation. “We believe that the creation of a new funding and research model can overcome many of the obstacles that currently prevent research breakthroughs. Working closely with our scientists and more than 30 industry partners, the Parker Institute is positioned to broadly disseminate discoveries and, most importantly, more rapidly deliver treatments to patients.”

      Read Full Article
      Mentions: Immunotherapy
    9. St. Jude Researchers Reveal How Two Types of Immune Cells Can Arise From One

      "The fates of immune cells can be decided at the initial division of a cell. Researchers at St. Jude Children’s Research Hospital have discovered that the production of daughter cells with different roles in the immune system is driven by the lopsided distribution of the signaling protein c-Myc. Nudging c-Myc in one direction or the other could make vaccines more effective or advance immunotherapies for cancer treatment. The research appears online today in the scientific journal Nature."

      Read Full Article
    10. UCLA Study Yields the Key to Effective Personalized Medicine

      "Unlike other approaches to personalized medicine currently being tested, PPM doesn’t require complex, time-consuming analysis of a patient’s genetic information or of the disease’s cellular makeup. Instead, it produces a personalized drug regimen based on information about a person’s phenotype — biological traits that could include anything from blood pressure to the size of a tumor or the health of a specific organ."

      Read Full Article
    11. Pediatric Researchers Find Evidence that Help Prevent Abnormalities in Heart Muscle after Children Receive Chemotherapy

      "The study in today’s issue of the journal Cancer, the journal of the American Cancer Society, finally provides new insight as to how dexrazoxane protects against heart damage in children receiving one of the most common treatment for childhood cancer, anthracycline chemotherapy. Dexrazoxane has recently been established by investigators at the Children’s Hospital of Michigan and elsewhere to effectively protect the heart from anthracycline-induced toxicity in childhood leukemia and other cancers, and as a result was recently officially designated an orphan drug by the U.S. Food and Drug Administration for the prevention of cardiomyopathy for children and ...

      Read Full Article
      Mentions: Chemotherapy
    12. Children's Hospital of Michigan DMC Research Team Leads Clinical Trial to Protect the Hearts of Children Who Receive Chemotherapy

      Published in the upcoming March 10, 2016 issue of the authoritative Journal of Clinical Oncology, this new study is likely to change the standard of cardiac care during treatment of many childhood cancer patients.

      Read Full Article
    13. Using New Drug Screening Tool, UNC Researchers Identify Potential Treatments for Ewing Sarcoma

      In a first-of-its-kind-study, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center discovered and applied a new screening technique capable of testing thousands of potential drug compounds to see if those compounds can reverse abnormal DNA unwinding in Ewing sarcoma, a bone and soft tissue cancer that's most common in teens and young adults.

      Read Full Article
      Mentions: Genetics
    14. Patients with Advanced Cancer Want to Know Their Genomics Test Results

      "An overwhelming majority of people with incurable cancer want to hear findings from DNA sequencing of their own tumors and normal cells, and to learn how those results may affect their health and treatment options, Dana Farber Cancer Institute scientists report.  The discovery highlights the need to improve patient education about genomics and to boost the resources available for the oncologists who interpret and present these findings to the patients."

      Read Full Article
      Mentions: Treatment Genetics
    15. Robert Seeger, MD, Selected for Prestigious Award From the Pediatric Blood and Marrow Transplant Consortium

      "Robert Seeger, MD, division head for Basic and Translational Research of the Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles (CHLA) has been selected for the 2016 Lifetime Achievement Award from the Pediatric Blood and Marrow Transplant Consortium (PBMC). As the eighth recipient of the prestigious award, Seeger is recognized for a career that exemplifies the mission of the PBMTC to support research and education to improve the availability, safety and efficacy of hematopoietic cell transplantation and other cellular therapeutics for children and adolescents.  Seeger, who has served as director of the Cancer Research Program in ...

      Read Full Article
      Mentions: NANT
    16. Laser Surgery Opens Blood-Brain Barrier to Chemotherapy

      "Using a laser probe, neurosurgeons at Washington University School of Medicine in St. Louis have opened the brain’s protective cover, enabling them to deliver chemotherapy drugs to patients with a form of deadly brain cancer.  In a pilot study, 14 patients with glioblastoma – the most common and aggressive type of brain cancer – underwent minimally invasive laser surgery to treat a recurrence of their tumors. Heat from the laser is known to kill brain tumor cells but, unexpectedly, the researchers found that the technology can penetrate the blood-brain barrier."

      Read Full Article
    17. Crafting a Better T Cell for Immunotherapy: New Technology, Not Yet Tested In Humans, Aims To Reduce Patients' Waiting Time, Increase Potency Of T-Cell Therapy

      "Although not yet tested in humans, the researchers believe this new approach could improve on current T-cell therapy methods in several ways:
      • by boosting the cells’ potency,
      • by growing larger numbers of cancer-fighting T cells,
      • by adding a potential “kill switch” to quickly deactivate the cells in patients’ bodies in the event of toxic side effects and
      • by cutting down the immune cell processing time from the current 14 to 20 days before reinfusion to 9 days or less."

      Read Full Article
      Mentions: Immunotherapy
    18. Unique Next Generation Sequencing-Based Panel Designed for Pediatric Cancer Research

      Unique Next Generation Sequencing-Based Panel Designed for Pediatric Cancer Research

      "Children’s Hospital Los Angeles (CHLA) and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay would be CHLA’s first NGS panel designed to target biomarkers associated with childhood cancers.  The NGS panel under development is a unique targeted DNA and RNA sequencing-based research gene panel. Its results could lead to better understanding of the pathogenesis and future therapy of pediatric cancer patients. It will utilize Thermo Fisher’s Ion Torrent NGS platform and Ion AmpliSeq technology."

      Read Full Article
    19. New Study Suggests More Than 8 Percent of Children with Cancer Have Genetic Predisposition

      "Researchers conducted next-generation DNA sequencing of both the tumor and normal tissues from 1,120 pediatric cancer patients and found that 8.5 percent of patients had pathogenic or likely pathogenic mutations of genes within their normal tissue that increase their risk of developing cancer. Prior to this study, the presence of such germline mutations in pediatric cancer patients was thought to be extremely rare and restricted to children in families with strong histories of cancer. This study revealed that more than half of the children with germline mutations lacked any family history of cancer."

      Read Full Article
    20. Viral Therapy in Melanoma Clinical Trial Led by Rutgers Cancer Institute Physician-Scientist is Approved by FDA

      The U.S. Food and Drug Administration has approved an immunotherapy known as T-VEC that was the focus of a phase III melanoma clinical trial led by Rutgers Cancer Institute of New Jersey Associate Director for Clinical Science and Chief Surgical Officer Howard L. Kaufman, MD, FACS.

      Read Full Article
    1-24 of 72 1 2 3 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video